“Scientists say that weight-loss drugs OjemPic and Wegovy also delay aging.”

“In addition to improving cardiovascular disease, extensive benefits, significantly suppressing infection-related deaths”,
,
,

‘Weight loss drug’ Ozempic and Wegovi
[Reuters=Yonhap News photo. Redistribution and DB prohibition],
,
, “(Yonhap News) A study has shown that Ozempic and Wegovi, widely used as ‘weight loss drugs’ after confirming their outstanding weight loss effects despite being developed as diabetes treatments, also delay aging in the body and lower mortality rates,”
,
, “The Guardian reported on the 31st (local time) that these results were announced at the European Society of Cardiology conference held last week in London.”
,
, “The main component of Ozempic and Wegovi, semaglutide, a hormone similar to GLP-1 (glucagon-like peptide-1) that promotes insulin secretion and suppresses appetite, has been confirmed in previous studies to reduce the risk of death in obese, overweight, and heart disease patients.”
,
, “However, this study found that semaglutide affects a much wider range of diseases such as arthritis, Alzheimer’s, cancer, and COVID-19, lowering overall mortality rates.”
,
, “Professor Helena Kronholz of Yale School of Medicine in the United States, who announced the research results, said, ‘Semaglutide had more extensive benefits than we initially imagined,’ adding, ‘Improving health in this way does not just avoid heart failure but promotes health. It’s not surprising that delaying the aging process actually occurs if people’s health is improved.'”
,
, “The study was conducted in the United States, where 17,604 individuals aged 45 and older who were overweight or obese, had cardiovascular disease but not diabetes, were given semaglutide or a placebo and tracked for over 3 years.”
,
, “During this period, a total of 833 individuals died, with 58% of deaths attributed to cardiovascular issues and 42% to other causes such as infection.”
,
, “The researchers confirmed that the semaglutide group had a lower probability of dying from infection compared to the placebo group, and cardiovascular problems continued to decrease steadily.”
,
, “One of the lead authors, Professor Benjamin Skirka of Harvard University, stated, ‘The significant reduction in non-cardiovascular mortality, especially infection-related mortality, is remarkable.'”
,
, ‘ [email protected]’,
,
,